8:00-8:30    Coffee

8:30-8:40    Chariperson's Remarks

8:40-9:10   Less is Better: The Essence of Leadlikeness
Dr. Tudor I. Oprea, University of New Mexico
Producing high quality leads relies on our ability to (1) systematically explore the low-MW chemical space and to (2) simultaneously optimize properties related to pharmacodynamics, pharmacokinetics and toxicology. The lead-like concept allows us to carefully investigate this space. Results from collaborations with Daylight and Chemical Diversity Labs will be discussed.

9:10-9:40    Challenges in Managing a Modern Treasury
Dr. Thomas Kraemer, Director, Medicinal Chemistry, Bayer HealthCare AG
Currently we face an enormous drive to improve the overall quality in drug discovery starting from the creation of a high quality screening collection until delivery of a high quality development candidate. Crucial factors associated with the assembly, quality improvement and management of a compound collection typically are: the availability of efficient sample logistics systems enabling optimal storage conditions, an agreement on and strict adherence to certain quality criteria, the acquisition of a well-balanced blend of compounds and libraries from different origin and a reliable IT-infrastructure for efficient sample handling. Topics that will be presented include our strategy of storing compounds, quality/purchase criteria for the extension of our collection and also results of a library profiling study.

9:40-10:10    Optimizing Storage, Handling and Overall Composition of a Pharmaceutical Compound Collection
Dr. Sandra Nelson, Section Head, Screening & Compound Repository, Procter & Gamble Pharmaceuticals 
The effects of storage under three conditions, which are used for our collection, were studied for 1 year on 800 representative compounds in DMSO. Compound concentration, purity and water uptake were measured for: 1) 4oC, dry 2) room temperature under N2, 3) room temperature, ambient atmosphere. The strategy for building this collection largely from commercially available compounds will be discussed.

10:10-10:30    Coffee Break 

10:30-11:15    Panel: Outsourcing of Library and Building Block Synthesis Sponsored by • Supply and Demand  • East versus West • Synthetic strategies and follow-up chemistry • Working out a basis for collaboration - Who does what  • Does the collaborating partner do design or synthesis • Hidden reagent costs - what to do when Aldrich & Sigma are not on the doorstep  Dr. Brian Moloney, Department Manager, Pharma, Evotec OAI  Dr. Nathan Collins,Vice President Chemistry New Products & Services Discovery Chemistry Division, Discovery Partners International Dr. Sorel Muresan, Associate Principal Scientist, Computational Chemistry, AstraZeneca plc Thomas Kraemer, Director, Medicinal Chemistry, Bayer HealthCare AG Dr. Sandra Nelson, Section Head, Screening & Compound Repository, P&G Pharmaceuticals

11:30-11:50    Development and Exploitation of Halogen Dance Chemistry Toward the Construction of Novel Functionalized Heterocycles
Dr. Garry Smith, Executive Vice President, Advanced Synthesis Group, Inc
Halogen dance chemistry of nitrogen containing heterocycles, in particular,
pyridine and thiazole, is being studied to identify reactivity profiles. The understanding of which allows the functionalization of heterocycles in ways that would be difficult or impossible through more classical means. The exploitation of these building blocks derived from the development of the halogen dance 
chemistry has allowed access to more advanced and novel core heterocycles.

12:00-1:30    Lunch on your own

1:30-3:00    Tutorial Catalysts-The Benefits of SFC to Discovery Research
Mr. William Farrell, Manager, High-Throughput Analysis & Purification, Global Research & Development, Pfizer Inc.
Dr. Dan B. Kassell, Senior Director, Drug Discovery, Syrrx, Inc.
Mr. Craig White, Analytical Technologies, Eli Lilly and Co.

3:00-3:30    Implementation and Innovations of Supercritical Fluid Chromatography within the Pharmaceutical Industry
Ms. Jennifer Lefler, Technical & Applications Consultant, Mettler Toledo 
AutoChemPacked column SFC (Supercritical Fluid Chromatography) is a robust and easy-to-use form of normal phase chromatography ideally suited to the analysis and purification of analytes with a wide range of molecular weight and polarity, i.e. drug like molecules. The intrinsic properties of supercritical carbon dioxide allows for faster optimum flow rates on long columns without the drawbacks of HPLC like: a large pressure drop across the column or inhibitory backpressure. SFC offers superior speed and efficiency yet complementary selectivity to HPLC. SFC can be implemented in the diverse arena of analytical and preparative chromatography. Analyses and purification of chiral and achiral molecules at a range of scales in combination with low consumption of volatile organic solvents has promoted the adoption of this "green" technology. To an end-user, SFC operates very similarly to HPLC, chromatographic selectivity can be achieved through choice of columns, modifier, additive, temperature, and pressure. For reasons listed above, the technique has enticed many pharmaceutical companies to utilize SFC as the chromatographic technique of choice. We wish to present to potential adopters and users of the technology our current product line and exemplary applications from our existing customer base.

Background Information 
Supercritical Fluid Chromatography (SFC) has been gaining interest as technique for the analysis and purification of small molecule pharmaceuticals. The most notable applications are for chiral and combinatorial separations, where SFC has demonstrated better separation efficiency and less solvent consumption than conventional approaches. Extending SFC as a separation tools for biomarker analysis, metabonomics, proteomics and even "walk-up" purification applications are just now being pursued. There are many misconceptions about how applicable SFC will be in these new areas. This presentation will aim to highlight the benefits of SFC, while providing the known practical limitations of the technique. 

4:00 End of Conference